Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: A meta-analysis of phase III randomized control trials
Evidence Based Medicine
Shao N et al. – Considering all the available Phase III trials, sequential adjuvant chemotherapy for early breast cancer seems to add a significant benefit in both disease–free survival (DFS) and overall survival (OS) over concurrent regimens.Methods
- All Phase III randomized trials comparing adjuvant chemotherapy of sequential or concurrent anthracyclines and taxanes in early-stage breast cancer patients were considered eligible.
- A total of three trials that enrolled 8728 women were analyzed.
- A pooled analysis was accomplished and event-based risk ratios (RR) with 95% confidence intervals (95%CI) were derived.
- The significant differences in disease-free survival (DFS) and overall survival (OS) were explored.
- A heterogeneity test was applied as well.
- Among three eligible trials, significant differences in favor of sequential regimen were seen in DFS (RR: 0.90; 95%CI: 0.84 to 0.98; P=0.01) and in OS (RR: 0.88; 95%CI: 0.79 to 0.98; P=0.02).